Logo image of BIO.B

BIO-RAD LABORATORIES -CL B (BIO.B) Stock Price, Forecast & Analysis

USA - New York Stock Exchange - NYSE:BIO.B - US0905721082 - Common Stock

310.7 USD
-3.7 (-1.18%)
Last: 11/17/2025, 8:04:00 PM

BIO.B Key Statistics, Chart & Performance

Key Statistics
Market Cap8.38B
Revenue(TTM)2.56B
Net Income(TTM)-675.90M
Shares26.97M
Float18.32M
52 Week High818.6
52 Week Low225.29
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)10.31
PE30.14
Fwd PE29.92
Earnings (Next)02-11
IPO1980-03-17
Sector
GICS SectorHealth Care
GICS IndustryLife Sciences Tools & Services
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
BIO.B short term performance overview.The bars show the price performance of BIO.B in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20

BIO.B long term performance overview.The bars show the price performance of BIO.B in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40

The current stock price of BIO.B is 310.7 USD. In the past month the price decreased by -8.89%. In the past year, price decreased by -48.29%.

BIO-RAD LABORATORIES -CL B / BIO.B Daily stock chart

BIO.B Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to BIO.B. When comparing the yearly performance of all stocks, BIO.B is a bad performer in the overall market: 83.82% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

BIO.B Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to BIO.B. BIO.B has an excellent financial health rating, but there are some minor concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BIO.B Financial Highlights

Over the last trailing twelve months BIO.B reported a non-GAAP Earnings per Share(EPS) of 10.31. The EPS decreased by -1.9% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -6.97%
ROE -10.03%
Debt/Equity 0.18
Chartmill High Growth Momentum
EPS Q2Q%12.44%
Sales Q2Q%0.5%
EPS 1Y (TTM)-1.9%
Revenue 1Y (TTM)-0.88%

BIO.B Forecast & Estimates

10 analysts have analysed BIO.B and the average price target is 363.55 USD. This implies a price increase of 17.01% is expected in the next year compared to the current price of 310.7.

For the next year, analysts expect an EPS growth of -1.94% and a revenue growth 0.31% for BIO.B


Analysts
Analysts76
Price Target363.55 (17.01%)
EPS Next Y-1.94%
Revenue Next Year0.31%

BIO.B Ownership

Ownership
Inst Owners92.44%
Ins Owners8.18%
Short Float %N/A
Short RatioN/A

About BIO.B

Company Profile

BIO.B logo image Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. The company is headquartered in Hercules, California and currently employs 7,700 full-time employees. The firm offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The company operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.

Company Info

BIO-RAD LABORATORIES -CL B

1000 Alfred Nobel Dr

Hercules CALIFORNIA US

CEO: Norman Schwartz

Employees: 7700

BIO.B Company Website

BIO.B Investor Relations

Phone: 15107247000

BIO-RAD LABORATORIES -CL B / BIO.B FAQ

What does BIO-RAD LABORATORIES -CL B do?

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. The company is headquartered in Hercules, California and currently employs 7,700 full-time employees. The firm offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The company operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.


Can you provide the latest stock price for BIO-RAD LABORATORIES -CL B?

The current stock price of BIO.B is 310.7 USD. The price decreased by -1.18% in the last trading session.


Does BIO-RAD LABORATORIES -CL B pay dividends?

BIO.B does not pay a dividend.


How is the ChartMill rating for BIO-RAD LABORATORIES -CL B?

BIO.B has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 4 out of 10.


Should I buy BIO.B stock?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BIO.B.


What is the market capitalization of BIO.B stock?

BIO-RAD LABORATORIES -CL B (BIO.B) has a market capitalization of 8.38B USD. This makes BIO.B a Mid Cap stock.


Can you provide the ownership details for BIO.B stock?

You can find the ownership structure of BIO-RAD LABORATORIES -CL B (BIO.B) on the Ownership tab.